Alpha 2.0
Login Register
» Authors » J A Ledermann

J A Ledermann

Explore the profile of J A Ledermann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 85
Citations 3140
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
N Colombo
R H Begent
K D Bagshawe
A Gonzalez-Martin
G J Rustin
J Sehouli
I Vergote
A du Bois
C Sessa
D J Kerr
Published In
Ann Oncol
Br J Cancer
Eur J Cancer
Gynecol Oncol
Eur J Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ledermann J, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, et al.
Ann Oncol . 2024 Feb; 35(3):248-266. PMID: 38307807
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June...
2.
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Gonzalez-Martin A, Harter P, Leary A, Lorusso D, Miller R, Pothuri B, et al.
Ann Oncol . 2023 Aug; 34(10):833-848. PMID: 37597580
No abstract available.
3.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
Sessa C, Balmana J, Bober S, Cardoso M, Colombo N, Curigliano G, et al.
Ann Oncol . 2022 Oct; 34(1):33-47. PMID: 36307055
No abstract available.
4.
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Frenel J, Kim J, Aryal N, Asher R, Berton D, Vidal L, et al.
Ann Oncol . 2022 Jun; 33(10):1021-1028. PMID: 35772665
Background: In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation significantly improved progression-free survival (PFS) and prolonged overall survival...
5.
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin A, Bosse T, Creutzberg C, Giornelli G, Harter P, Joly F, et al.
Ann Oncol . 2022 Jun; 33(9):860-877. PMID: 35690222
No abstract available.
6.
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study
Ledermann J, Zurawski B, Raspagliesi F, De Giorgi U, Arranz Arija J, Romeo Marin M, et al.
ESMO Open . 2021 Dec; 7(1):100311. PMID: 34920291
Background: Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with...
7.
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
Colombo N, Ledermann J
Ann Oncol . 2021 Jul; 32(10):1300-1303. PMID: 34293462
No abstract available.
8.
The systemic treatment of recurrent ovarian cancer revisited
Baert T, Ferrero A, Sehouli J, ODonnell D, Gonzalez-Martin A, Joly F, et al.
Ann Oncol . 2021 Mar; 32(6):710-725. PMID: 33675937
Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to...
9.
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
Ledermann J, Embleton-Thirsk A, Perren T, Jayson G, Rustin G, Kaye S, et al.
ESMO Open . 2021 Feb; 6(2):100043. PMID: 33610123
Background: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in...
10.
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer
Hall M, Dehbi H, Banerjee S, Lord R, Clamp A, Ledermann J, et al.
Gynecol Oncol . 2020 Oct; 159(3):692-698. PMID: 33077258
Background: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer. Patients And...